Heterogeneous treatment effects of adjuvant therapy for patients with cervical cancer in the intermediate‐risk group
Ayumi Taguchi(Daiichi-Sankyo (Japan)), Munetaka Takekuma(Shizuoka Cancer Center), Konan Hara(University of Arizona), Chihiro Ishizawa(The University of Tokyo), Akiko Furusawa(Tokyo Metropolitan Komagome Hospital), Aikou Okamoto(Jikei University School of Medicine), Michihiro Tanikawa(The University of Tokyo), Y. Nakajima(University of Nottingham), Kenbun Sone(University of Tokyo Hospital), Muneaki Shimada(Tokyo Metropolitan Ohtsuka Hospital), Mayuyo Mori(The University of Tokyo), Kosuke Kato(The University of Tokyo)
Cited by 10
Related Papers
Isolation of a possible archetypal JC virus DNA sequence from nonimmunocompromised individuals
|Journal of Virology|1990|327
Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas
|Clinical Cancer Research|2009|310
Trastuzumab Deruxtecan in Patients With <i>HER2</i>-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial
|Journal of Clinical Oncology|2023|293
High Incidence of Urinary JC Virus Excretion in Nonimmunosuppressed Older Patients
|The Journal of Infectious Diseases|1990|238